189 results about "Small intestine" patented technology

The invention relates to a nanoparticle system for small intestine delivery, which is used for delivering exogenous miR-122-5p to the intestinal tract and comprises a miRNA-protamine compound inner core, a liposome middle layer wrapping the inner core and a p123 functional shell wrapping the liposome. Due to the adoption of the technical scheme, a nano-targeting delivery technology is combined with paternal epigenetic programming intervention for the first time, and a brand-new nano-drug treatment thought is provided for intergenerational genetic diseases caused by exposure of environmental adverse factors. By delivering exogenous miR-122-5p to the intestinal tract, the miRNA spectrum unbalanced due to exposure of paternal BaP can be directly improved.

The invention relates to the technical field of image processing, in particular to a small intestine capsule endoscope target detection method which comprises the following steps: acquiring a small intestine capsule endoscope image; the method comprises the following steps: constructing an improved RT-DETR network, inserting an SCSA module between a backbone network and a neck network of the RT-DETR, and introducing a DFM module behind a three-branch Fusion module of the neck network; and the improved RT-DETR network adopts a Focaler-IoU loss function. According to the method, the problem that the accuracy of recognizing the tumor target by using the small intestine capsule endoscope image through RT-DETR needs to be further improved is solved.

The present invention provides, in part, compositions comprising a peptide that is larazotide or larazotide derivative, or salt thereof, contained within a matrix that provides for controlled release and sustained release formulations. The present invention contemplates that these compositions, formulations and methods can be useful for treating diseases and disorders of the small bowel.

The invention provides a method for evaluating the minimum inhibitory concentration of compound amoxicillin powder, and belongs to the technical field of compound amoxicillin, and the method comprises the following steps: (1) simulating a gastric acid environment, and respectively adding different compound amoxicillin powder samples to obtain different sample solutions; (2) simulating a small intestine environment for different sample solutions obtained in the step (1); and (3) sampling different sample solutions after the step (2), measuring the minimum inhibitory concentration, and comparing the effect of the compound amoxicillin powder sample to evaluate. The invention provides a method for evaluating the minimum inhibitory concentration of compound amoxicillin powder. The method is simple to operate and can quickly and accurately evaluate the effect of the compound amoxicillin powder.

The application provides bifidobacterium longum MG-G763 for improving constipation, and belongs to the technical field of microorganisms. The bifidobacterium longum MG-G763 provided by the application can effectively relieve constipation by integrating multiple effects such as nerve regulation, immune regulation, barrier repair and flora regulation, and systematically restoring intestinal function homeostasis. The bifidobacterium longum MG-G763 can significantly improve the defecation particle number and defecation weight of constipated mice, shorten the time for defecating the first black stool, improve the small intestinal transport rate of the mice, effectively improve and relieve the defecation condition of the constipated mice, and significantly increase the amount of intestinal beneficial bacteria and reduce the amount of harmful bacteria, thereby promoting intestinal health.

The present invention relates to an artificial digestive tract tissue for training in endoscopic submucosal dissection (ESD) and a method for manufacturing the same. Specifically, the invention relates to an artificial digestive tract tissue configured to mimic the mucosal layer, submucosal layer, and muscle layer constituting the human digestive tract tissue in a multilayer structure, such that swelling occurs upon liquid injection and a color change occurs due to changes in salt concentration, and to a casting and curing-based hydrogel molding process for manufacturing the same. According to the present invention, the problems associated with existing animal tissue-based ESD training simulators can be resolved, repeated use is possible, and training tailored to the structural characteristics of specific organs (stomach, large intestine, small intestine, etc.) is possible.

The invention belongs to the technical field of medicinal and edible products, and particularly relates to a composition for improving constipation and diarrhea as well as a preparation method and application thereof. The composition for improving constipation and diarrhea provided by the invention comprises the following raw materials in parts by weight: Chinese yam, resistant dextrin, ginseng, radix ophiopogonis, poria cocos, dogwood, semen coicis, aronia melanocarpa freeze-dried powder, mulberry, radix polygonati officinalis, lycium ruthenicum freeze-dried powder, fructo-oligosaccharide and crystalline fructose. Experiments prove that through synergistic cooperation of the raw materials, the composition can effectively improve the diarrhea index of diarrhea rats, improve the intestinal barrier function, increase the villus length of small intestine tissues, reduce the depth of crypts, increase the water content of excrement of constipation mice and promote intestinal peristalsis, and has the effect of bidirectionally regulating diarrhea and constipation; the intestinal barrier function can be favorably repaired.

The utility model relates to the technical field of enteroscopes, in particular to an adjustable pulley fixator for an outer sleeve of an enteroscope, which comprises a bed edge fixing device capable of being arranged on a bed edge, a movable adjusting support arranged on the bed edge fixing device and an outer sleeve fixator arranged on the movable adjusting support. And a slidable module capable of fixing the outer sleeve is arranged on the outer sleeve fixer. The enteroscope can further promote the popularization of the enteroscope, and is expected to be clinically transformed.

This invention discloses a natural polysaccharide-based multilayer composite encapsulated probiotic and its preparation method, relating to the field of functional food and microbial preparation technology. This invention provides metabolic substrates for the probiotics through a probiotic-prebiotic co-encapsulation core located in the innermost layer, enabling them to maintain physiological activity during encapsulation. The first anionic polysaccharide encapsulation layer uses sodium alginate, which forms a three-dimensional gel network in a calcium-ion-containing curing solution. In the acidic environment of the stomach, the carboxyl groups in the calcium alginate gel undergo carboxylation, and the network shrinks and densifies, effectively blocking the invasion of hydrogen ions and pepsin, thus physically isolating the probiotics from gastric juice. When the encapsulated probiotics enter the small intestine and colon, the chitosan in the second pH-responsive composite encapsulation layer undergoes a conformational change due to amino deprotonation. Simultaneously, phosphate and citrate ions in the outer environment exchange ions with calcium alginate, achieving a triggered release of the probiotics in the colon.

Aspects of the present disclosure relate to compositions and methods for treating one or more inflammatory bowel diseases ("IBD"), such as ulcerative colitis ("UC") and / or Crohn's disease. Some embodiments relate to a pharmaceutical dosage form comprising a core comprising an inhibitor of a protease (e.g., a bacterial protease) and a controlled release coating applied to an outer surface of the core. In some cases, the protease inhibitor is a gligliptin or a pharmaceutically acceptable salt thereof. In some cases, the controlled release coating is configured to release the protease inhibitor in the large intestine (e.g., colon) and / or small intestine of a subject administered the pharmaceutical dosage form. Some embodiments relate to methods of treating one or more IBDs comprising delivering a therapeutically effective amount of an inhibitor of a protease (e.g., bacterial protease) to the large intestine (e.g., colon) and / or the small intestine of a subject.

The invention discloses a preparation method and application of sheep small intestine immunomodulatory protein, and belongs to the field of functional protein preparation. The preparation method comprises the following steps: carrying out phosphate buffer low-temperature low-salt extraction on freeze-dried powder of small intestines of sheep, carrying out gel column chromatography and anion exchange column chromatography separation and purification, and further carrying out high performance liquid chromatography analysis and activity evaluation to obtain the protein component with immunoregulatory activity. The sheep small intestine protein prepared by the method has no cytotoxicity, can promote the proliferation of macrophages RAW264.7 and enhance the NO release capability of cells, has an obvious promotion effect on the secretion of TNF-alpha and IL-6 by the cells, and has relatively high immunoregulation activity, so that a scientific basis is provided for the application of the sheep small intestine protein in the development of functional foods and medicines for enhancing immunoregulation; the development and utilization value of livestock by-products is improved.

The application discloses a compound plant essential oil preparation for improving intestinal tract barrier function of laying hens and a preparation method thereof, relates to the technical field of livestock and poultry intestinal tract health regulation, and comprises microcapsule particles with a multilayer structure, which sequentially comprises a core layer, a first coating layer, an intermediate functional layer and a second coating layer; the compound plant essential oil preparation for improving intestinal tract barrier function of laying hens and the preparation method thereof are characterized in that the preparation is arranged as a multilayer microcapsule structure composed of the core layer, the first coating layer, the intermediate functional layer and the second coating layer in sequence, and the first coating layer and the second coating layer adopt enteric polymers with different pH dissolution ranges, so that the intermediate functional layer can be released first in the pH environment from the duodenum to the jejunum, and the core layer is released subsequently in the pH environment of the ileum, thereby realizing the graded and zoned release of active components of plant essential oils in the front and rear sections of the small intestine of laying hens, and matching different essential oil components with the barrier repair requirements of each section of the intestinal tract.

Formulations containing pH-sensitive nanoparticles for the enteric delivery of therapeutic agents are provided. The nanoparticles include a pH-sensitive polymer that protects the therapeutic agent against degradation in the stomach and allows it to be released in the small intestine or colon. The nanoparticle formulation is particularly effective at protecting sensitive biotherapeutic agents from degradation when administered orally, and makes it possible to avoid administration of such agents by injection. Also provided are methods for producing the formulations, as well as methods of treating diseases employing the formulations.

The invention relates to the technical field of pharmaceutical preparations, in particular to an EPA phospholipid soft capsule composition and a preparation method thereof.The composition comprises EPA phospholipid and an enteric soft capsule shell, the EPA phospholipid is prepared from EPA ethyl ester and a reaction substrate under the action of immobilized phospholipase, and the enteric soft capsule shell comprises an enteric material, a plasticizer and purified water. According to the EPA phospholipid enteric-coated soft capsule provided by the invention, EPA ethyl ester is phosphatidylated, and EPA phospholipid is prepared into the enteric-coated soft capsule, so that stable retention of a medicine in the stomach can be reduced, accurate dissolution of the medicine in the small intestine is realized, the problems of peculiar smell and degradation caused by release of EPA ethyl ester in the stomach are effectively avoided, and the EPA phospholipid enteric-coated soft capsule has the characteristic of pH-enzyme dual response.

To provide new functions of dried young barley grass. [Solution] An agent for improving the absorption of propionic acid and / or butyrate in the small intestine, comprising dried young barley leaves as the active ingredient.

The present application belongs to the field of food technology, and particularly relates to a Pickering emulsion containing menthol and a preparation method thereof. The Pickering emulsion containing menthol is prepared by taking menthol and cyclodextrin composite particles as a solid particle emulsifier and soybean oil as an oil phase, and the mass ratio of the menthol to the cyclodextrin is 1:2-5. The Pickering emulsion containing menthol prepared by the present application exhibits good storage stability and rheological properties within 30 days, and in addition, the emulsion also exhibits excellent antioxidant and antibacterial properties. In an in vitro simulated digestion experiment, the release rate of free fatty acids in the emulsion in the small intestine is 76.64+ / -1.08%, and the emulsion has good sustained-release property and improves the bioavailability of menthol.

The invention discloses rumen bypass choline chloride particles and a preparation method thereof, and belongs to the technical field of feed additives. The rumen bypass choline chloride particle comprises a drug-loading inner core and an outer protective layer coating the drug-loading inner core, the drug-loading inner core is obtained by mixing hydrophobic particles with a melt, extruding and granulating; wherein the hydrophobic particles are obtained by wrapping crystal form choline chloride with a hydrophobic material; the molten liquid is obtained by melting and mixing stearic acid, magnesium stearate and oleophylic cellulose; the oleophylic cellulose adopts ethyl cellulose; the outer protective layer is obtained by mixing fatty acid, hydrogenated grease, a pH sensitive material and a fragrant raw material with fruit fragrance, green grass fragrance or fermentation fragrance; the outer protective layer of the rumen bypass choline chloride particle is good in toughness and fitness, the rumen bypass choline chloride particle is good in rumen bypass effect and good in small intestine release rate, the food intake of dairy cows is not affected, the risk of metabolic diseases is effectively reduced, and the health level of the dairy cows is improved.

The utility model relates to the field of medical auxiliary instrument treatment, in particular to an enteroscope cannula lifting device. Comprising a connecting part and a fixing ring part arranged at one end of the connecting part, and a connecting rope is formed at the end, away from the fixing ring part, of the connecting part; the lifting device further comprises a locking structure arranged at the end, away from the fixing ring part, of the connecting rope, and the locking structure can be fixedly connected with the connecting rope so that the connecting rope can form a hand ring part capable of surrounding the hand of a person. The device is simple in structure and easy to operate, and the existing problems are effectively solved.

The invention belongs to the technical field of biological medicine, and discloses an antibody for treating advanced rectal cancer and application thereof.The antibody is a monoclonal antibody 3C1 of targeted carcino-embryonic antigen (CEA), the sequence of a heavy chain variable region (VH) of the antibody is as shown in SEQ ID NO: 1, the sequence of a light chain variable region (VL) of the antibody is as shown in SEQ ID NO: 5, and the indirect ELISA detection titer reaches 1: 512000; also provided is an antibody conjugate (ADC) in which the antibody and raltitrexed are coupled by a linker, the drug-antibody ratio (DAR) being 3.0-4.0, the monomer purity being greater than or equal to 95%; the antibody conjugate (ADC) can be used for treating CEA positive advanced rectal cancer, animal experiments show that the tumor inhibition rate of ADC is 86% (significantly higher than 35% of free raltitrexed), the weight loss rate of mice is low, the toxicity of small intestines is light, the problems that existing drugs are poor in targeting and high in toxicity are solved, and the antibody conjugate has the advantages of high efficiency and safety.

This utility model discloses a high-efficiency pretreatment device for heparin sodium raw materials, relating to the technical field of meat product processing equipment. It includes a processing box with an opening and closing door installed on its outer wall. An installation horizontal plate is fixed inside the processing box, and a drive plate is positioned above the installation horizontal plate. Multiple mucosal scrapers are fixed to the bottom of the drive plate. Multiple through holes are drilled through the installation horizontal plate for the mucosal scrapers to pass through. Clamping clamps are installed on the bottom of the installation horizontal plate to the side of the through holes, and are used to clamp the small intestine. Multiple water supply pipes are installed on the inner wall of the processing box, located below the installation horizontal plate. A water outlet pipe is connected to the bottom of the processing box. A support frame is fixed to the inner wall of the processing box, located below the water supply pipes. A filter plate is slidably connected to the top of the support frame. The device integrates washing, separation, and secondary cleaning within the same processing box, allowing for direct mucosal separation and cleaning of the mucosa after small intestine cleaning.

This invention discloses a single-herb bezoar preparation based on an ancient prescription; an enteric-coated bezoar soft capsule and its preparation method. The enteric-coated bezoar soft capsule consists of a bezoar dispersion and an enteric-coated soft capsule shell. A sand mill is used to prepare bezoar powder into micron-sized particles with a particle size ≤100μm. The micron-sized bezoar powder is fully dispersed in a dispersion medium, thereby improving the solubility of bezoar. The single-herb bezoar preparation can improve the problem of inconsistent bezoar content in compound bezoar preparations. The process of preparing the ≤100μm micron-sized bezoar dispersion uses non-metallic grinding equipment, avoiding the catalytic reaction of metal ions during the preparation of micron-sized powder. Low-temperature grinding is also used to avoid denaturation of the heat-sensitive active substances in bezoar, better preserving its biological activity. The enteric-coated formulation prevents the drug from being released in the stomach until it reaches the small intestine, avoiding the precipitation of bilirubin and other bile acids in the acidic environment of the stomach, which would otherwise lead to insoluble solids and poor solubility.

The utility model relates to sausage processing technical field discloses a kind of wire dismounting and dividing devices for sausage processing, including workbench, the workbench top is fixedly connected with side plate, the workbench top is provided with dismounting and dividing assembly, the wire dismounting and dividing assembly includes support plate, the support plate bottom is fixedly connected in the side plate top, the support plate one side is fixedly connected with fixed plate, the fixed plate top is fixedly connected with motor, the motor output end is fixedly connected with winding roller.In the utility model, through the rotation of winding roller driven by motor, the small intestine head and product fragments generated when wire dismounting are dropped into the inside of collecting box through round steel grate, so as to realize automatic wire dismounting, reduce the effect of impurities mixed into product, solve the problem that small intestine head and product fragments can be mixed into product to affect product quality, and improve personnel labor efficiency.

This invention relates to the field of pharmaceutical formulation technology, specifically to a sustained-release formulation of rifabutin, and more specifically, to a sustained-release rifabutin formulation composition for treating Helicobacter pylori infection. The key technical point of this invention is that it uses a novel antibiotic for treating Helicobacter pylori infection as the active ingredient, supplemented with specific inactive ingredients, including a hydrophilic gel-type matrix sustained-release material, a swelling agent, a buoyancy aid, and a lubricant. Through the synergistic effect of the hydrophilic gel-type matrix sustained-release material, the swelling agent, and the buoyancy aid, the composition can rapidly swell in gastric juice and maintain a floating state, thereby significantly prolonging the residence time of the formulation in the stomach and upper small intestine. This invention solves the technical problem of conventional formulations having a short residence time in the stomach and requiring frequent administration to maintain an effective antibacterial concentration, achieving the goal of effectively eradicating Helicobacter pylori by reducing the number of doses while maintaining an effective concentration at the site of infection for a longer period.

The invention discloses a sequential enzymatic-ionic synergistic soybean protein isolate modification method, which comprises the following steps: dispersing soybean protein isolate in water to prepare a protein solution, adding glutamine transaminase, carrying out heating reaction to inactivate enzyme to obtain an enzyme cross-linked protein solution, adding MgCl2 into the enzyme cross-linked protein solution, and carrying out heating reaction to induce protein aggregation to obtain a modified soybean protein isolate solution; and cooling to room temperature after the reaction is finished. The invention also discloses an application of the soybean protein product obtained by the sequential enzymatic-ionic synergistic soybean protein isolate modification method as a food additive. According to the method, the sensitization of the soybean protein can be remarkably reduced, meanwhile, the unique stomach resistance-intestinal efficient release dynamic characteristic is shown, and the small intestine peptide fragment release amount is promoted to be increased.

This invention relates to a targeted ileal delivery method for endotoxin chelating agents, their preparation, and applications, belonging to the technical field of pharmaceutical formulations. The drug comprises a specific polymer copolymer containing a three-dimensional framework of organic carbon-carbon chemical bonds and amino groups. The aim is to deliver the polymer chelating agent to the distal small intestine for release, thereby chelating pathogen-associated molecular patterns produced by intestinal microorganisms, including endotoxins and CpG-DNA. The complex formed by the polymer chelating agent and pathogen molecular patterns released in the ileum can be excreted from the digestive tract, thereby reducing inflammation and alleviating various metabolic diseases.

The invention discloses a dietary compound containing resveratrol and application of the dietary compound in improvement of inflammatory injury of diabetic nephropathy, and belongs to the field of functional foods and dietary supplements. The L-WPI is taken as a carrier, so that the phosphorus load of a final product is reduced from the source, the problem that the hyperphosphatemia risk of a DKD patient is possibly aggravated by a conventional whey protein raw material is solved, and the L-WPI is more suitable for nutrition intervention of people with renal hypofunction. The L-WPI-Res compound constructed through heat treatment induction can effectively protect Res from being excessively degraded in a harsh stomach acidic and enzymatic hydrolysis environment, realizes stomach stability and intestinal targeted release, improves the biological accessibility of the compound in a small intestine stage by 20-35% compared with a free monomer, fundamentally solves the bottleneck problem of low oral availability of polyphenol compounds, and has a wide application prospect. Meanwhile, the L-WPI-Res-55 DEG C compound has a synergistic enhancement effect in two aspects of regulating blood sugar potential and relieving inflammation.

The gastric bypass device includes an obstruction device adapted to be positioned against the patient's pyloric sphincter and a liner extending distally from the obstruction device. A tether extends from the obstruction device. A dynamic leash can be secured to the obstruction device and can cooperate with the tether to help hold the obstruction device in place.

The application provides a platelet-responsive self-gelation hemostatic material and a preparation method and application thereof, and belongs to the medical field. Based on a multiple cross-linking strategy of dynamic covalent bonds and non-covalent interactions, a hemostatic material capable of realizing self-gelation quickly is designed by using modified sodium alginate and hydroxylated porcine small intestinal submucosa as raw materials. The hemostatic material has good hydrophilicity and liquid absorption capacity, can realize powder-gelation transformation in a short time, form a stable physical barrier, has platelet response characteristics, can promote platelet adhesion and activation, accelerate the blood coagulation process of the body, and improve the mechanical properties and tissue adhesion of the material, and has a good application prospect.

The invention relates to a preparation method and application of acellular extracellular matrix hydrogel for organoid culture, and the method comprises the following steps: step (1): preparing a small intestine acellular scaffold: sequentially putting pig small intestines without adipose tissues into a first solution, a second solution, a third solution and a fourth solution, stirring, and freezing and freeze-drying to obtain the small intestine acellular scaffold; step (2): preparing small intestine acellular matrix hydrogel, cutting a small intestine acellular scaffold into small pieces or grinding the small intestine acellular scaffold into powder, preparing a small intestine acellular scaffold solution with a hydrochloric acid solution and a pepsase solution, centrifuging, adding a PBS solution to terminate digestion, and adjusting the pH value to 6.0-8.0 to obtain solution state small intestine acellular matrix hydrogel; and gelling the solution-state small intestine extracellular matrix hydrogel at the temperature of 37 DEG C for 20-60 minutes to obtain the gel-state small intestine extracellular matrix hydrogel which is used for culturing alimentary canal organs.

Compositions and principles for use before parturition in the prophylactic treatment of hypocalcemia in ruminant animals include compositions having phosphate binders for the prophylactic treatment of parturient hypocalcemia in ruminant animals. These compositions are presented in unit dosage forms, with one or more doses administered daily to the gastrointestinal tract of the ruminant animal, or in wet form. The composition contains one or more phosphate binders and one or more nutrients selected from minerals, vitamins, and amino acids, as well as a composition that includes an inhibitor of the small intestinal Na-phosphate transporter for the prophylactic treatment of parturient hypocalcemia in ruminant animals. Phosphate binders are selected from aluminum, iron, sevelamer, and lanthanum salts, with either inorganic or organic acids, hydrates thereof, or any mixture thereof.